Preoperative Evaluation of the Patient With Pulmonary Disease

Bapoje, Srinivas R.; Whitaker, Julia Feliz; Schulz, Tara; Chu, Eugene S.; Albert, Richard K.

doi:10.1378/chest.07-0347

Cited by 115 publications

(70 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Especially in COPD patients it is important to prevent vertebral fractures since they might result in a decreased forced vital capacity [14]. In addition, (osteoporotic) hip fractures in COPD patients pose a greater problem than hip fractures in otherwise healthy subjects because of the increased operative risk in COPD patients [15][16][17].…”

mentioning

confidence: 99%

Current status of research on osteoporosis in COPD: a systematic review

Graat‐Verboom

Wouters²,

Smeenk³

et al. 2009

Eur Respir J

249

218

View full text Add to dashboard Cite

Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of osteoporosis. However, the prevalence, correlates and effectiveness of treatment of osteoporosis in COPD patients remain unclear.We performed a systematic review of the literature to answer three questions. 1) What is the prevalence of osteoporosis in COPD? 2) What are identified correlates of osteoporosis in COPD? 3) What are the effects of treatment of osteoporosis in COPD? A computerised literature search in MEDLINE/PubMed and the Cochrane database was carried out. In addition, reference lists were searched by hand and authors were contacted if necessary.The prevalence of osteoporosis and osteopenia varied 9-69% and 27-67%, respectively. Prevalence of osteoporosis was generally higher than in healthy subjects and some other chronic lung diseases. Correlates of osteoporosis in COPD are mainly measures of body composition, disease severity and the use of corticosteroids, although causality has not been proven. Effects of treatment of osteoporosis have not been investigated in samples consisting of COPD patients only.Longitudinal follow-up to assess determinants of osteoporosis in COPD and randomised placebo-controlled trials on the effects of treatment of osteoporosis in patients with COPD only are warranted.

show abstract

mentioning

confidence: 99%

Current status of research on osteoporosis in COPD: a systematic review

Graat‐Verboom

Wouters²,

Smeenk³

et al. 2009

Eur Respir J

249

218

View full text Add to dashboard Cite

show abstract

“…43 In patients who are taking anticoagulants, an international normalized ratio above 1.5 should be managed, delaying the procedure, with vitamin K supplementation or fresh-frozen plasma, depending on the cause and urgency. The usage of new oral anticoagulants (ie, dabigatran, rivaroxaban) is becoming more common.…”

Section: Laboratory Workupmentioning

confidence: 99%

Hip Fracture in the Elderly

Urrutia¹,

Zamora²,

Klaber³

2017

CMGer

View full text Add to dashboard Cite

Hip fractures in elderly patients are the most severe form of fragility fractures. They can lead to significant morbidity and mortality; additionally, they have an enormous economic and social burden. Treatment of hip fractures in elderly patients should be based on a prompt initial evaluation, followed by surgical treatment without unnecessary delays under a collaborative effort of a multidisciplinary team. Postoperative care should be started immediately after surgery, and it must include an intensive rehabilitation, as well as treatment of osteoporosis and any other metabolic imbalance. This review incorporates current literature on initial evaluation and definitive management of hip fractures in the elderly and is intended to assist practitioners of different specialties treating these patients.

show abstract

“…Complications were determined to be 17 times higher in patients with a cardiopulmonary risk index higher than 4 as compared to patients with a cardiopulmonary risk index lower than 4 [11].…”

Section: ) General Health Statusmentioning

confidence: 99%

“…Patients with pulmonary hypertension (PH) undergoing noncardiac surgery (right ventricular systolic pressure >35 mm Hg) have higher risks for postoperative congestive heart failure, cardiac ischemic events, arrhythmias, stroke, respiratory failure (the most common cause of morbidity), hepatic dysfunction, renal dysfunction, or the need for postoperative positive inotropic or vasopressor agent [11].…”

Section: ) Pulmonary Hypertensionmentioning

confidence: 99%